Dollar Struggles as Policy Uncertainty Weighs on Markets Despite Official Support 
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
South Korea Industry Minister Heads to Washington Amid U.S. Tariff Hike Concerns 
Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Russia Stocks End Flat as MOEX Closes Unchanged Amid Mixed Global Signals 
U.S. Government Faces Brief Shutdown as Congress Delays Funding Deal 
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Lotte Group is set to acquire a bioindustry CMO plant located in the United States. The move has been announced on Thursday, May 5, and this also signals the company’s entrance into the bio business.
Currently, the acquisition process for the contract manufacturing organization (CMO) facility is still ongoing. Investment banking industry insiders said that Lotte Group has taken this step to buy the CMO plant after it stated that the bioindustry will be its new growth engine.
According to The Korea Times, CMOs are firms that specialize in the production of biopharmaceuticals that were developed by other companies. Lotte Group’s new CMO business will be headed by Lee Won Jik, a former executive at Samsung Biologics that the company recently hired. He has been tasked to develop and grow this business unit that the Lotte Group set up.
Lee will also be leading the acquisition efforts of the CMO as per the report. It was only last month when the South Korean multinational conglomerate declared during its general shareholders' meeting that its next growth engine for the future will be the bioindustry. Lotte Holdings will be investing directly in this business and will provide support to help it grow and succeed.
Meanwhile, as part of its entrance into the CMO business, Lotte Group applied for a trademark for its new biz. The company registered “Lotte Biologics” with the Korean Intellectual Property Office (KIPO) to officially launch its bio venture.
It was added that under the new Lotte Biologics banner, Lotte will also be participating in the largest bioindustry expo in the world called the Bio International Convention (Bio USA) which is set to take place next month in San Diego, California.
KIPO revealed that Lotte Holdings applied for the patent last week and aside from the name, it also trademarked some business areas such as customized manufacturing of biopharmaceuticals and drug processing and medical diagnostic devices for virus testing, The Korea Herald reported.
“Registering the trademark of Lotte Biologics was a part of preparations for the group’s bio business,” an official of Lotte Holdings stated. “We are reviewing various ways to enter the bio industry, but nothing has been confirmed at the moment.”
